CJC-1295: Structure, Chemistry & Scientific Research Overview (2026)

CJC-1295 is a synthetic peptide built to mimic growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates growth hormone (GH) release. As a GHRH analog, it targets GHRH receptors on somatotroph cells of the anterior pituitary, the cell type responsible for endogenous GH secretion.

Researchers have modified its amino acid sequence to resist enzymatic breakdown, which native GHRH is highly susceptible to. This gives CJC-1295 greater enzymatic stability than the hormone it’s modeled after.

You’ll encounter two main variants in the literature:

• CJC-1295 with DAC: attaches to albumin for extended activity
• CJC-1295 without DAC: shorter half-life, closer to native GHRH behavior

Both versions act as agonists at the GHRH receptor, a class B G protein-coupled receptor that signals through cAMP; the variants differ mainly in their half-life.

Your understanding of CJC-1295 begins with attempts to engineer a more stable version of Growth Hormone-Releasing Hormone. Native GHRH breaks down quickly in biological systems, so researchers focused on modifying its structure to resist enzymatic degradation without losing receptor-binding function.

ConjuChem Biotechnologies played a key role in this work, applying its DAC albumin-binding technology to extend the peptide’s half-life and create the compound now known as CJC-1295.

You’ll find that early research relied heavily on animal models, including GHRH knockout mice, to clarify how GHRH receptor pathways influence growth hormone regulation. These models helped researchers confirm mechanisms of action and evaluate receptor specificity.

As analytical tools advanced, your access to reliable data on CJC-1295 improved significantly. Techniques such as mass spectrometry and chromatography now allow scientists to verify:

• Peptide purity
• Structural identity
• Batch-to-batch consistency

This progress continues to shape how CJC-1295 is studied today.

You’ll find that CJC-1295 differs from native GHRH through specific amino acid substitutions built to withstand laboratory handling better than the original sequence. These changes rely on established peptide engineering principles, aimed at limiting enzymatic breakdown while keeping the peptide’s core structural framework intact.

As with other synthetic peptide analogs, you’re looking at a chain of amino acids linked by covalent peptide bonds, forming a linear molecule. The specific sequence and chemical adjustments shape key physical and chemical traits, including:

• Solubility
• Charge distribution
• Molecular flexibility
• Behavior during analytical testing

To examine these properties, you’d typically rely on tools such as computational modeling, spectroscopy, chromatography, and molecular dynamics simulations, which help clarify peptide conformation and stability.

You will find two distinct versions of this peptide in research contexts, separated by a single structural feature: the DAC albumin-binding modification.

CJC-1295 without DAC, also called Mod GRF 1-29 or Modified GRF (1-29), does not carry this modification. Without albumin binding, its reported half-life is about 30 minutes, much shorter than that of the DAC version.

Your choice between the two depends on whether your experimental design calls for sustained or short-lived receptor stimulation.

Your understanding of CJC-1295 begins with its origin in the active segment of Growth Hormone-Releasing Hormone, modified with specific amino acid substitutions designed to improve stability.

You can confirm the exact sequence through standard laboratory techniques, including:

• Peptide sequencing
• Amino acid analysis
• Mass spectrometry

These methods matter because even a single altered residue can change how the peptide behaves in analytical testing.

The composition also tells you about:

• Net molecular charge
• Water affinity
• Structural flexibility

These factors shape the peptide’s overall physical and chemical characteristics.

CJC-1295 shows you how targeted engineering can alter a molecule’s behavior without a full redesign.

Research in this area typically covers:

• Amino acid substitutions and their functional effects
• Enzymatic stability under varying conditions
• Peptide folding patterns
• Structural flexibility and rigidity trade-offs
• Receptor binding specificity
• Degradation pathways at the molecular level
• Chemical modifications to extend function
• Protein interactions within biological systems

These areas give you a broader picture of how synthetic biomolecules are designed and refined.

When you evaluate CJC-1295 in a laboratory setting, you assess a defined set of physical and chemical attributes that affect how it behaves in solution and storage.

These properties collectively shape how the peptide behaves in solution and in assay systems.

Tracking these parameters allows you to maintain reproducibility across experiments and to compare results generated in different laboratory environments.

Beyond its interaction with the GHRH receptor, you’ll find CJC-1295 used as a working model in several related scientific fields:

• Peptide chemistry: examining structural stability and modification effects
• Receptor biology: mapping how synthetic analogs bind and activate targets like GHRH-R
• Analytical chemistry: refining mass spectrometry and chromatography methods for peptide verification
• Manufacturing science: informing synthesis and quality control processes for other peptide compounds

Because CJC-1295 has undergone extensive characterization, you can regard it as one of the more well-documented synthetic peptides available for comparative research purposes.

CJC-1295 is a lab-made peptide built to mimic Growth Hormone-Releasing Hormone (GHRH), an endogenous hypothalamic signaling peptide.

Its structure is engineered for research purposes, giving scientists a tool to study:

• Peptide chemistry and how synthetic analogs behave compared to natural hormones
• Receptor biology, including how GHRH receptors respond to this compound
• Molecular interactions between the peptide and target cells

You’ll find CJC-1295 referenced primarily in laboratory and academic settings, where researchers examine its properties at a molecular level.

DAC refers to an albumin-binding chemical modification developed by ConjuChem.

It is a chemical addition attached to one version of CJC-1295 to change how the molecule behaves.

This modification is what separates CJC-1295 with DAC from the no-DAC version you may see referenced elsewhere.

Key points to understand:

• DAC binds the peptide to albumin, an abundant plasma protein.
• This binding action is what extends the peptide’s activity over a longer period.
• Without DAC, the peptide lacks this attachment and has a much shorter half-life.

Knowing this distinction helps you understand why the two versions are used differently in research designs.

Yes, CJC-1295 is a synthetic peptide.

You get it through manufacturing methods that build the peptide chain in a lab, not through extraction from natural sources.

Its structure is confirmed using standard analytical techniques, which verify purity and consistency across batches.

You verify CJC-1295 identity and purity using several standard laboratory techniques:

• HPLC: separates and quantifies peptide components
• LC-MS: confirms molecular identity through mass detection
• Amino acid analysis: checks composition accuracy
• Peptide sequencing: validates structural integrity

You typically receive CJC-1295 as a lyophilized powder, in sealed vials to preserve stability during shipping and storage.

For in-vitro work, laboratories reconstitute the powder in a suitable solvent such as bacteriostatic water, following their standard laboratory procedures.

Standard handling steps include:

• Storage: keep lyophilized vials refrigerated or frozen until use
• Reconstitution: add bacteriostatic water using sterile technique
• Documentation: record purity testing results (HPLC or LC-MS) from the batch Certificate of Analysis, available upon request

Your specific procedures may differ based on the requirements of your laboratory and the design of your experiment.

CJC-1295 stands as a solid example of how modifying a peptide’s structure can change its stability and behavior in the lab.

When you study this compound, you gain insight into:

• How sequence modifications affect molecular stability
• Analytical methods used to characterize peptide behavior
• Receptor interaction patterns relevant to peptide research

As synthesis techniques, chromatography methods, and structural analysis tools continue to advance, you’ll find CJC-1295 remains a useful reference point for understanding synthetic peptide design principles.

NuRev supplies CJC-1295 strictly for laboratory research use only; it is not for human or veterinary use.